ANXA5 and acute myeloid leukemia: The cells derived from AML patients showed an apoptotic response after 72 h blebbistatin treatment (analyzed by CD34+ and annexin V double staining), whereas samples from normal donors showed low sensitivity to blebbistatin (Figure 4F).